SG10202112135VA - Purification of rapamycin derivatives - Google Patents

Purification of rapamycin derivatives

Info

Publication number
SG10202112135VA
SG10202112135VA SG10202112135VA SG10202112135VA SG10202112135VA SG 10202112135V A SG10202112135V A SG 10202112135VA SG 10202112135V A SG10202112135V A SG 10202112135VA SG 10202112135V A SG10202112135V A SG 10202112135VA SG 10202112135V A SG10202112135V A SG 10202112135VA
Authority
SG
Singapore
Prior art keywords
purification
rapamycin derivatives
rapamycin
derivatives
Prior art date
Application number
SG10202112135VA
Other languages
English (en)
Inventor
Richard S Fornicola
Ivan Kovacik
Leelakrishna Kondaveti
Aniruddh Singh
Margaret W Kayo
Original Assignee
Biosensors International Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosensors International Group Ltd filed Critical Biosensors International Group Ltd
Publication of SG10202112135VA publication Critical patent/SG10202112135VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10202112135VA 2013-03-15 2014-03-17 Purification of rapamycin derivatives SG10202112135VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361799857P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10202112135VA true SG10202112135VA (en) 2021-12-30

Family

ID=51538094

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202112135VA SG10202112135VA (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives
SG10201707632PA SG10201707632PA (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives
SG11201507406YA SG11201507406YA (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201707632PA SG10201707632PA (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives
SG11201507406YA SG11201507406YA (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives

Country Status (8)

Country Link
US (5) US9598439B2 (https=)
EP (1) EP2972258B1 (https=)
JP (4) JP2016519086A (https=)
CN (2) CN105102967B (https=)
CA (1) CA2901162C (https=)
ES (1) ES2897473T3 (https=)
SG (3) SG10202112135VA (https=)
WO (1) WO2014145780A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715150B2 (en) 2009-11-02 2014-05-06 Pulse Therapeutics, Inc. Devices for controlling magnetic nanoparticles to treat fluid obstructions
WO2014145780A1 (en) 2013-03-15 2014-09-18 Biosensors International Group, Ltd. Purification of rapamycin derivatives
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
CN116102576B (zh) * 2021-11-09 2025-08-29 上海博畅医疗科技有限公司 一种优美莫司晶体的制造方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
WO2004089958A2 (en) * 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
EP1697383B1 (en) * 2003-12-05 2014-04-23 Biocon Limited Process for the purification of tacrolimus
JP4716280B2 (ja) * 2004-03-01 2011-07-06 テルモ株式会社 O−アルキル化ラパマイシン誘導体の製造法
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン42−エステル誘導体の位置特異的合成
CA2584430A1 (en) 2004-12-01 2006-06-08 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Methods for preparing pimecrolimus
RU2007130406A (ru) * 2005-03-02 2009-04-10 Вайет (Us) Очистка рапамицина
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
CN101394867A (zh) 2006-03-07 2009-03-25 惠氏公司 大环内酯类免疫抑制剂的水溶性聚乙二醇结合物的制备方法
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US20100029933A1 (en) * 2006-11-10 2010-02-04 Biocon Limited Pure form of rapamycin and a process for recovery and purification thereof
EP2090580B1 (en) 2006-11-27 2014-06-04 Terumo Kabushiki Kaisha Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
CN101077334A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 含酪氨酸激酶抑制剂的抗癌组合物
TW200948361A (en) 2008-05-26 2009-12-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Method for synthesizing Biolimus A9 and the like and method for improving stability of the same
US20100055145A1 (en) * 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
WO2010124098A2 (en) 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Use of drug polymorphs to achieve controlled drug delivery from a coated medical device
CN102464669B (zh) * 2010-11-17 2014-04-16 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
WO2014145780A1 (en) 2013-03-15 2014-09-18 Biosensors International Group, Ltd. Purification of rapamycin derivatives

Also Published As

Publication number Publication date
WO2014145780A4 (en) 2014-11-20
US10597406B2 (en) 2020-03-24
US10202402B2 (en) 2019-02-12
CN105102967B (zh) 2018-10-12
CN105102967A (zh) 2015-11-25
HK1218959A1 (zh) 2017-03-17
EP2972258A4 (en) 2016-12-21
US11046711B2 (en) 2021-06-29
ES2897473T3 (es) 2022-03-01
SG10201707632PA (en) 2017-11-29
US20160002262A1 (en) 2016-01-07
US20220024947A1 (en) 2022-01-27
CN108864149A (zh) 2018-11-23
SG11201507406YA (en) 2015-10-29
JP2019089848A (ja) 2019-06-13
JP2016519086A (ja) 2016-06-30
EP2972258A1 (en) 2016-01-20
JP2023164476A (ja) 2023-11-10
CA2901162A1 (en) 2014-09-18
JP2021121601A (ja) 2021-08-26
US20190256527A1 (en) 2019-08-22
CN108864149B (zh) 2022-04-05
US11780850B2 (en) 2023-10-10
US20170334928A1 (en) 2017-11-23
EP2972258B1 (en) 2021-08-04
WO2014145780A1 (en) 2014-09-18
CA2901162C (en) 2021-06-01
US9598439B2 (en) 2017-03-21
US20200270272A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
IL242453B (en) Bipyrazole derivatives as jak inhibitors
PL2803401T3 (pl) Oczyszczanie powietrza
IL240863A0 (en) Amatoxin derivatives
PL2953944T3 (pl) Pochodne pirydazynonowe-amidowe
AR092198A1 (es) Derivados de pirazolopirimidinas
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
ZA201604502B (en) Use of benzimidazole-proline derivatives
LT3027598T (lt) Oksochinazolinil-butanamido dariniai
ZA201602831B (en) Use of lactones
HUE037606T2 (hu) Imidazopirazinon-származékok
SG11201507406YA (en) Purification of rapamycin derivatives
SG11201505719TA (en) Low temperature synthesis of rapamycin derivatives
GB201314581D0 (en) Purification